LEXX · XBRL financial data
Lexaria Bioscience financial statements, every fiscal year
The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (LEXX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | †Aug 31, 2021 | Aug 31, 2022 | Aug 31, 2023 | Aug 31, 2024 | Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 315 | 723 | 255 | 226 | 464 | 706 |
| Revenue from contracts with customers | 385 | 723 | 255 | 226 | 464 | — |
| Cost of goods and services sold | 99 | 175 | 72 | 32 | 5 | 3 |
| Gross profit | 285 | 547 | 184 | 195 | 459 | 703 |
| Research and development | 387 | 1,263 | 1,843 | 3,667 | 2,361 | 8,239 |
| General and administrative | 293 | 4,971 | 5,725 | 3,062 | 3,852 | 4,345 |
| Total operating expenses | 4,370 | 6,234 | 7,567 | 6,729 | 6,213 | 12,584 |
| Operating income (loss) | — | (5,687) | (7,384) | (6,534) | (5,753) | (11,881) |
| Other income (expense) | — | — | (765) | (179) | (56) | — |
| Income tax expense (benefit) | 2 | 6 | 0 | — | — | — |
| Net income (loss) | (4,085) | (4,186) | (7,269) | (6,665) | (5,795) | (11,902) |
| Earnings per share, diluted USD per share | — | — | — | (1.01) | (0.47) | (0.66) |
| Weighted average shares, diluted thousands of shares | — | — | — | 6,614 | 12,384 | 17,999 |
- † Share count changed about 1/16 in the period ending 2021-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (LEXX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | †Aug 31, 2021 | Aug 31, 2022 | Aug 31, 2023 | Aug 31, 2024 | Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1,294 | 10,918 | 5,813 | 1,352 | 6,500 | 1,802 |
| Short-term investments | — | — | — | — | — | 143 |
| Marketable securities | 19 | 834 | 347 | 126 | 56 | 22 |
| Marketable securities, non-current | — | — | — | 14 | 14 | 349 |
| Accounts receivable | 314 | 342 | 202 | 175 | 154 | 368 |
| Inventory | 117 | 30 | 38 | 0 | — | — |
| Prepaid and other current assets | — | — | — | 547 | 1,188 | 1,133 |
| Total current assets | 1,926 | 12,443 | 6,978 | 2,200 | 7,898 | 3,468 |
| Property and equipment, net | 483 | 368 | 316 | 254 | 255 | 228 |
| Right-of-use asset | 127 | 91 | — | 167 | 167 | 135 |
| Total assets | 2,828 | 13,267 | 7,834 | 3,084 | 8,868 | 4,175 |
| Total current liabilities | 226 | 153 | 194 | 268 | 1,099 | 1,493 |
| Lease liability, non-current | 89 | 50 | — | — | 109 | 79 |
| Total liabilities | 346 | 203 | 201 | 404 | 1,209 | 1,572 |
| Accumulated deficit | (27,802) | (31,829) | (39,099) | (45,763) | (51,559) | (63,461) |
| Total stockholders' equity | 2,525 | 13,064 | 7,949 | 3,044 | 8,036 | 2,990 |
| Total liabilities and equity | 2,828 | 13,267 | 7,834 | 3,084 | 8,868 | 4,175 |
| Common shares outstanding (cover page) thousands of shares | 90,044 | 5,727 | 5,951 | 10,277 | 17,453 | 22,226 |
- † Share count changed about 1/16 in the period ending 2021-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (LEXX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | †Aug 31, 2021 | Aug 31, 2022 | Aug 31, 2023 | Aug 31, 2024 | Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (4,085) | (4,186) | (7,269) | (6,665) | (5,795) | (11,902) |
| Stock-based compensation | — | 410 | 753 | 170 | 492 | 859 |
| Depreciation and amortization | — | — | — | — | 42 | 51 |
| Net cash from operating activities | (2,663) | (3,990) | (4,879) | (5,881) | (4,959) | (10,450) |
| Purchases of property and equipment | 0 | — | 49 | 34 | 43 | 25 |
| Net cash from investing activities | (27) | 194 | (181) | (170) | (189) | (243) |
| Proceeds from issuing common stock | — | — | — | — | 4,209 | 6,046 |
| Proceeds from issuing equity | 2,668 | 9,471 | 0 | 1,590 | — | — |
| Proceeds from long-term debt | 31 | — | — | — | — | — |
| Repayments of long-term debt | — | 23 | 0 | — | — | — |
| Net cash from financing activities | 2,699 | 13,420 | (45) | 1,590 | 10,315 | 6,046 |
| Net change in cash | — | — | — | (4,461) | 5,148 | (4,698) |
- † Share count changed about 1/16 in the period ending 2021-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Lexaria Bioscience | 3,500 | 0 | (1,635)* | 24.8M | 2.2 quarters | 10-QMay 31, 2026 |
| Kala Bio | 229 | not reported | (1,535)* | 19.3M | 4.7 quarters | 10-QJun 30, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Dyadic International | 1,425 | 961 | (1,818)* | 36.4M | 1.7 quarters | 10-QJun 30, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Aytu Biopharma | 26,308 | 16,106* | 4,406* | 10.9M | — | 10-KJun 30, 2026 |
| Tenax Therapeutics | 118,000 | 0* | (14,150)* | 37.4M | 8.3 quarters | 10-QJun 30, 2026 |
| Nanoviricides | 2,794 | not reported | (2,122)* | 25.5M | 1.3 quarters | 10-KJun 30, 2026 |
| Lisata Therapeutics | 10,443 | 0 | (2,649)* | 9.0M | 3.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.